|Bid||2.0400 x 800|
|Ask||2.4600 x 1300|
|Day's Range||2.1150 - 2.2343|
|52 Week Range||1.9900 - 11.2800|
|Beta (3Y Monthly)||2.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.40|
CAMBRIDGE, Mass., Nov. 14, 2019 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced.
ATLAS™ identifies naturally occurring neoantigen-specific inhibitory T cell responses that are augmented after vaccination Inhibitory T cell responses exacerbate tumor growth.
Proportions of inhibitory neoantigens found in cancer patients with the ATLAS™ biology-driven platform may also predict patient responses to immunotherapy Confirm positive.
Generated unprecedented 98% GEN-009 immune response frequency with ATLAS™Continued advancement of GEN-011, expect to file an IND in first half of 2020Entered into a common stock.
CAMBRIDGE, Mass., Oct. 17, 2019 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its.
The five-day European Society of Medical Oncology, or ESMO, Congress 2019 is set to conclude Tuesday in Barcelona, Spain. Touted as a congress where the exchange of translational cancer science of excellence ...
Today, we're taking a close look at Genocea (GNCA) to show why the stock could bounce back after fluctuating significantly over the last year.
Additional positive GEN-009 clinical immunogenicity data driven by ATLAS™ to be presented at ESMO Company to present at the Cantor Fitzgerald 2019 Global Healthcare Conference.
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
CAMBRIDGE, Mass., Aug. 30, 2019 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that.
Cancer. Research shows nearly every sixth death in the world is due to the disease, making it the second leading cause of death behind cardiovascular diseases. The global pharmaceutical industry is estimated ...
Initiated Part B of Phase 1/2a clinical trial of neoantigen vaccine candidate GEN-009;Plans to present additional GEN-009 immunogenicity data at ESMO 2019 Conference call.
CAMBRIDGE, Mass., July 18, 2019 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, will host its.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Investors need to pay close attention to Genocea Biosciences (GNCA) stock based on the movements in the options market lately.
All the shares in the offering will be sold by Genocea. In addition, Genocea expects to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock sold in the public offering. SVB Leerink and Stifel are acting as joint book-running managers for the offering.
Genocea Biosciences (NASDAQ: GNCA ) shares rallied higher after the company presented results from lead neoantigen vaccine at the annual meeting of the American Society of Clinical Oncology 2019. Genocea ...
The results were presented in a poster over the weekend at this year’s Annual Meeting of the American Society of Clinical Oncology (ASCO 2019). In the five patients for whom immune response results are available to date, GEN-009 monotherapy elicited T cell responses to 91% of the vaccine neoantigens administered.
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...
Poster presentation tomorrow, June 1st at 8:00 am CT in Poster Hall A Conference call and webcast to discuss results Monday, June 3rd at 8:30 am ET CAMBRIDGE, Mass., May 31,.